Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
News|Videos|September 3, 2026
4 Endocrinology Headlines You Missed in August 2026
Author(s)Chelsie Derman
Fact checked by: Tim Smith
New approval for tirzepatide, phase 3 wins for avexitide and retatrutide, and a GLP-1 telehealth safety gap in August's biggest endocrinology stories.
Advertisement
Advertisement
August brought a wave of movement across
Related to this article
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.
New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.
Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.
Lasker Award winners Takehisa Kitazawa and Tomoyuki Igawa discuss prophylaxis gains, remaining unmet needs, and lessons for drug discovery.
In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.
Advertisement
Advertisement